Centre for Drug Research, Universiti Sains Malaysia, Penang, Malaysia (DS, BV); School of Social Sciences, Universiti Sains Malaysia, Penang, Malaysia (SN); Department of Pharmacology, College of Graduate Studies, Midwestern University, Downers Grove, IL(WCP); National Institute on Drug Abuse Intramural Research Program, Baltimore, MD (KES); Department of Clinical, Pharmaceutical and Biological Sciences, School of Life and Medical Sciences, College Lane, Hatfield, United Kingdom (OC); Pinney Associates, Bethesda, MD and Johns Hopkins University School of Medicine, Baltimore, MD (JEH); Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL (OG).
Send correspondence to Darshan Singh, PhD, Centre for Drug Research, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia. E-mail: [email protected].
Received 3 March, 2021
Accepted 27 April, 2021
The authors report no conflicts of interest.
JEH, through PinneyAssociates, consults on the development of new pharmacotherapies for a broad range of medical disorders including for treatment of substance use disorders, along with consulting on kratom science and regulatory policy.
We thank Universiti Sains Malaysia (USM) for providing us the Research University (RU) Grant (No: 1001/CDADAH/8016108).
Kirsten Elin Smith, This research was supported in part by the Intramural Research Program of the NIH NIDA.